Can COX-2 inhibitor-induced increase in cardiovascular disease risk be modified by essential fatty acids?

Journal of Association of Physicians of India

Volumn 53, Issue JUL, 2005, Pages 623-627

  Das, U N ^a  

^a UND Life Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; ESSENTIAL FATTY ACID; PROSTAGLANDIN SYNTHASE INHIBITOR;

CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; HUMAN; METABOLISM; REVIEW; RISK FACTOR;

CARDIOVASCULAR DISEASES; CYCLOOXYGENASE INHIBITORS; ENZYME INHIBITORS; FATTY ACIDS, ESSENTIAL; HUMANS; RISK FACTORS;

EID: 24644433843     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Vu D, Murty M, McMorran M. Selective COX-2 inhibitors: suspected cardiovascular/cerebrovascular adverse reactions. Can Adverse React Newl 2002;12:2-3.
2. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-9.
3. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002;360:1071-3.
4. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004;351:1709-11.
5. Meyer CH, Gahler R. Central retinal vein occlusion in a patient with rheumatoid arthritis taking rofecoxib. Lancet 2002;360:1100.
6. Marcus AJ, Broekman MJ, Pinsky DJ. COX inhibitors and thromboregulation. New Engl J Med 2002;347:1025-6.
7. Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, Mirick G, Moussignac R-L. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammatory signals. J Exp Med 2002;196:1025-37.
8. Huang YS, Drummond R, Horrobin DF. Protective effect of gamma-linolenic acid on aspirin induced gastric hemorrhage in rats. Digestion 1987;36:36-41.
9. Manjari V, Das UN. Effect of polyunsaturated fatty acids on dexamethasone-induced gastric mucosal damage. Prostaglandins Leukot Essen Fatty Acids 2000;62:85-96.
10. Das UN. Beneficial effect(s) of n-3 fatty acids in cardiovascular diseases: but, why and how? Prostaglandins Leukot Essen Fatty Acids 2000;63:351-62.
11. Li Y, Kang JX, Leaf A. Differential effects of various eicosanoids on the production or prevention of arrhythmias in cultured neonatal rat cardiac myocytes. Prostaglandins 1997;54:511-30.
12. Das UN. Prostaglandins and cardiac arrhythmias. Med J Australia 1981;2:157.
13. Das UN. Prostacyclin as an endogenous anti-arrhythmic agent. Basic Res Cardiol 1983;78:716-9.
14. Albert CM, Campos H, Stampfer MJ, Ridker PM, Manson JE, Willett WC, Ma J. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med 2002;346:1113-8.
15. Pai JK, Pischon T, Ma J, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004;351:2599-610.
16. Das UN. A perinatal strategy to prevent coronary heart disease. Nutrition 2003;19:1022-7.
17. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004;350:1387-97.
18. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease. Application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.
19. Kumar GS and Das UN. Effect of prostaglandins and their precursors on the proliferation of human lymphocytes and their secretion of tumor necrosis factor and various interleukins. Prostaglandins Leukot Essen Fatty Acids 1994;50:331-4.
20. Endres S, Ghorbani R, Kelley VE, et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med 1989;320:265-71.
21. Fernandez-Real J-M, Vendrell J, Broch M, Ricart W. Insulin resistance, inflammation, and serum fatty acid composition. Diabetes Care 2003;26:1362-8.
22. Mohan IK and Das UN. Effect of L-arginine-nitric oxide system on the metabolism of essential fatty acids in chemical-induced diabetes mellitus. Prostaglandins Leukot Essen Fatty Acids 2000;62:35-46.
23. Egan KM, Lawson JA, Fries S, Koller B, Rader EM, Fitzgerald GA. COX-2-derived prostacyclin confers atheroprotection on female mice. Science 2004;306:1954-7.
24. Claria J, Serhan CN. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci USA 1995;92:9475-9.
25. 4 receptor transgenic mice reveal novel protective roles for lipoxins and aspirin-triggered lipoxins in reperfusion. J Clin Invest 1999; 104: 309-316.
26. Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN. Lipid mediator class switching during acute inflammation signals in resolution. Nat Immunol 2001;2:612-9.
27. 4 accelerate resolution of allergic edema in Angiostronglus costaricensis-infected rats: relationship with concurrent eosinophilia. J Immunol 2000;164:1029-36.
28. 4 stable analogs that block transmigration and adhesion of human neutrophils. Biochemistry 1995;34:14609-15.
29. Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, Gronert K. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med 2000;192:1197-1204.
30. Marcheselli VL, Hong S, Lukiw WJ, Tian XH, Gronet K, Musto A, Hardy M, Gimenez JM, Chiang N, Serhan CN, Bazan NG. Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J Biol Chem 2003;278:43807-17.
31. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9.
32. Das UN. Is metabolic syndrome X an inflammatory condition? Exp Biol Med 2002;227:989-97.
33. Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin-6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286:327-34.
34. Das UN. Essential fatty acid metabolism in patients with essential hypertension, diabetes mellitus and coronary heart disease. Prostaglandins Leukot Essen Fatty Acids 1995;52:387-91.
35. Arita M, Bianchini F, Aliberti J, Sher A, Chiang N, Hong S, Yang R, Petasis NA, Serhan CN. Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med 2005;201:713-22.
36. Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, Gronert K. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med 2000;192:1197-1204.
37. Calon F, Lim GP, Yang F, Morihara T, Teter B, Ubeda O, Rostaing P, Triller A, Salem N Jr, Ashe KH, Frautschy SA, Cole GM. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron 2004;43:633-45.
38. Kato T, Hancock RL, Mohammadpour H, McGregor B, Manalo P, Khaiboullina S, Hall MR, Pardini L, Pardini RS. Influence of omega-3 fatty acids on the growth of human colon carcinoma in nude mice. Cancer Lett 2002;187:169-77.
39. Das UN. A perinatal strategy to prevent adult disease : The role of long-chain polyunsaturated fatty acids. Kluwer Academic Press, Boston, 2002.